Results 231 to 240 of about 104,119 (333)

Higher Education as a Driver for the Humanization of Pediatric Pain Care (HUPEDCARE): Protocol of a Multicenter Study. [PDF]

open access: yesEur J Investig Health Psychol Educ
Gómez-Cantarino S   +13 more
europepmc   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf   +8 more
wiley   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong   +10 more
wiley   +1 more source

Age-related behavioral and molecular landmarks in new mouse models for studying Alzheimer's disease in Down syndrome. [PDF]

open access: yesAlzheimers Dement
Baniowska MR   +18 more
europepmc   +1 more source

A Framework for Impression Management in Extra‐Financial Reporting

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This paper examines how organisations employ impression management tactics in extra‐financial reporting, particularly in the context of environmental, social and governance (ESG) concerns. As stakeholder scrutiny and regulatory expectations intensify, organisations increasingly shape non‐financial disclosures to influence perceptions of ...
Laura Ribeiro   +3 more
wiley   +1 more source

Humans--a threat to humanity.

open access: yesSouth African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008
openaire   +2 more sources

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy